BiotechTube

NKTR-255 at 1.5 µg/kg + NKTR-255 at 3.0 μg/kg + NKTR-255 at 3.0/6.0 μg/kg

Phase 2/3Terminated
0 watching 0 views this week📈 Rising
60
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkin Lymphoma

Conditions

Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma

Trial Timeline

Dec 23, 2022 → Aug 16, 2024

NCT ID
NCT05664217

About NKTR-255 at 1.5 µg/kg + NKTR-255 at 3.0 μg/kg + NKTR-255 at 3.0/6.0 μg/kg

NKTR-255 at 1.5 µg/kg + NKTR-255 at 3.0 μg/kg + NKTR-255 at 3.0/6.0 μg/kg is a phase 2/3 stage product being developed by Nektar Therapeutics for Non-Hodgkin Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05664217. Target conditions include Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Hype Score Breakdown

Clinical
22
Activity
15
Company
5
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT05664217Phase 2/3Terminated

Competing Products

20 competing products in Non-Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
52
TazemetostatEisaiPhase 2
52
ONTAKEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
ONO-7018 + ONO-7018Ono PharmaceuticalPhase 1
33
gemcitabineEli LillyPhase 2
52
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
52
LY4152199 - IVEli LillyPhase 1
33
LY317615Eli LillyPhase 2
52
LY4584180 + RituximabEli LillyPhase 1
33
PirtobrutinibEli LillyPhase 2
52
Palbociclib + Sunitinib + Temsirolimus + Trastuzumab and Pertuzumab + Vemurafenib and Cobimetinib + Regorafenib + Olaparib + Nivolumab and Ipilimumab + Abemaciclib + Talazoparib + Atezolizumab and Talazoparib + Tucatinib plus Trastuzumab Subcutaneous (SC) + Futibatinib + Dabrafenib plus Trametinib + Fam-Trastuzumab Deruxtecan-Nxki (TDxD)Eli LillyPhase 2
52
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
77
HRS-3738Jiangsu Hengrui MedicinePhase 1
33
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
52
azacitadine + venetoclax + rituximab / IDEC-C2B8 + rituximab / IDEC-C2B8AbbViePhase 1/2
41
Epcoritamab + Cyclophosphamide + Rituximab + Doxorubicin + Vincristine + Prednisone + LenalidomideAbbViePhase 1/2
41
Siltuximab + EpcoritamabAbbViePhase 1
33

Other Products from Nektar Therapeutics

NKTR-102 + Eribulin + Ixabepilone + Vinorelbine + Gemcitabine + Paclitaxel + Docetaxel + Nab-paclitaxelPhase 3
72
NKTR-181 BID tablets + Placebo to match NKTR-181 BID tabletsPhase 3
72
NKTR-102 + Treatment of Physician's Choice (TPC)Phase 3
72
NKTR-181 BID tabletsPhase 3
72
aerosolized vancomycin or gentamicinPhase 2
47